Imara’s IMR-687 saw its Phase Transition Success Rate (PTSR) surge by 14 and 6 points in sickle cell disease and beta thalassaemia, respectively. The update occurred on 15 June on the heels of Phase IIa data reported at the 2021 European Hematology Association (EHA) Annual Congress, held virtually on 9-17 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.
The 93-patient Phase IIa found a 40% lower mean annualised vaso-occulsuive crises (VOC) rate for IMR-687 relative to placebo, including an average of 169 days until first VOC for treated patients compared to 87 days for placebo patients, according to an 11 June company press release. The press release also reported an increase in fetal hemoglobin (HbF)—the subject of the trial’s primary endpoint, though there was no specific data listed. The PTSR of IMR-687 in sickle cell disease and beta thalassaemia stands at 64% and 28%, respectively.
The Phase IIa update led to a 6-point bump in the drug’s Likelihood of Approval (LoA) for sickle cell disease, rising to 28%. However, there was no increase in the LoA for beta thalassaemia, which sits at 1%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.
Imara has a market cap of $137.2m.
William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.